dsip

isolated 1977 as a sleep peptide. 50 years of trials, no clinical breakthrough. community uses it anyway.

tier C · focus · Schoenenberger sleep peptide '77

verdict

delta sleep-inducing peptide. isolated 1977. 50 years of trials, no clinical breakthrough, persistent community responder reports.

if you're asking whether DSIP improves sleep — sometimes. the rabbit EEG work is genuine, the 1980s human sleep trials produced real positive signals, and the alcohol-withdrawal literature is more substantial than most people realize. community responders are bimodal but real. when it works for someone, it seems to actually work, particularly for sleep onset and depth. when a compound has had 50 years of runway and still cannot produce consistent trial results, the honest read is that the effect is narrow, real, and unpredictable.

if you're asking what receptor DSIP hits — nothing anyone has confirmed. studied for sleep modulation, stress response, and alcohol withdrawal with mixed results. the biological effects are real enough to keep research interest alive across decades, but no receptor has ever been pinned down. that's part of why no clean modern dosing framework exists.

if you came in via the cost-of-experimenting angle — inexpensive on the research-chemical market, with minimal side-effect reports across decades. responder stories exist; a clean modern responder framework does not. responder reports are bimodal: some subjects respond, others show nothing, and no protocol adjustment is documented to convert a non-responder.

based on published evidence and disclosed clinical practice. not medical advice.

why C-tier

C-tier because DSIP has had nearly 50 years of on-again off-again clinical research without producing convergent evidence of efficacy. Some positive trials exist, particularly for sleep and alcohol withdrawal, but the field never reached consensus and the compound never achieved drug-approval status anywhere. The mechanism is unclear: no confirmed receptor, no clean pathway. Not D-tier because the trial literature is real and includes legitimate positive findings, the peptide is well-characterized biochemically, and community responders do seem to exist. Not B-tier because the gap between 'occasionally shown to help' and 'consistently shown to help' is exactly what separates C from B.

the core tension

DSIP has an unusual profile: it's been around for nearly fifty years, it has real clinical literature (mostly from the 1980s), and the field just never converged on whether it works. Some trials showed sleep and stress benefits. Others showed nothing. The mechanism is unclear: no confirmed receptor, no clean pathway. The community keeps using it because the occasional responder reports a genuine effect. This is a compound that has had plenty of time to prove itself and hasn't.

what it is

dsip (delta sleep-inducing peptide) is a 9-amino-acid neuropeptide isolated in 1977 from the cerebral venous blood of rabbits whose sleep had been electrically induced. monnier's basel group named it for its association with delta-wave sleep. plasma half-life is minutes, which has complicated clinical development from the start.

what it does

binds nothing anyone has confirmed. the biological effects are real enough to keep research interest alive across decades, but no receptor has ever been pinned down. studied for sleep modulation, stress response, and alcohol withdrawal, with mixed results. community use is mostly sleep-focused, but no modern dosing framework has been validated.

origin

discovered by marcel monnier and colleagues at the university of basel in 1977. its major clinical trial wave ran through the 1980s in sleep, stress, and addiction medicine, particularly in eastern europe. then it just sat there. no decisive positive trial, no decisive negative trial, no convergence. an april 22 2026 fda 503a update removed emideltide from category 2 pending pcac consultation in july 2026.

why researchers are interested

community responders are bimodal but real. when it works for someone, it seems to actually work, particularly for sleep onset and depth. side effect reports are minimal across decades of use. it is also cheap on the research-chemical market, which lowers the cost of finding out if you are a responder.

does it work

sometimes. the rabbit eeg work is genuine, the 1980s human sleep trials produced real positive signals, and the alcohol-withdrawal literature is more substantial than most people realize. but fifty years is a very long time to fail to converge. when a compound has had this much runway and still cannot produce consistent trial results, the honest read is that the effect is narrow, real, and unpredictable. responder stories exist; a clean modern responder framework does not.

claims vs the data

• induces delta-wave sleep — partially true — The original rabbit work and some early human EEG studies supported this. Later trial replication has been inconsistent. The effect, when present, is modest.
• improves sleep quality in insomnia — weak — Several 1980s clinical trials in insomnia patients reported benefits; others showed no effect versus placebo. No convergent modern clinical consensus.
• reduces stress-related symptoms — partially true — Some Russian and European clinical work supports anxiolytic and stress-buffering effects, often in the context of alcohol withdrawal protocols. Effect sizes are modest and trial quality is variable.
• helps alcohol withdrawal — partially true — A legitimate historical clinical application in Eastern European medicine. Not a modern first-line treatment, but the trial base is more substantial than for most DSIP indications.
• extends lifespan or slows aging — overreach — Occasionally marketed with longevity language. Not supported by any meaningful clinical or rodent data, this is marketing drift.

key facts

• molecular formula: C35H48N10O15
• molecular weight: 848.8 Da
• amino acids: 9
• half-life: very short in plasma (minutes); degraded rapidly by peptidases, which has complicated clinical development throughout its history
• type: nonapeptide (9 amino acids)
• CAS: 62568-57-4
• 1977 discovered in rabbit brain
• 49 years since discovery with no approved use
• mixed sleep-trial results across decades
• none confirmed receptor target

frequently asked questions

What is DSIP?

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring 9-amino-acid neuropeptide first isolated from rabbit cerebral venous blood in 1977. Named for its ability to induce delta-wave (deep) sleep patterns in preclinical studies.

What does DSIP do?

DSIP has been studied for sleep modulation, stress response regulation, and opioid withdrawal support. Preclinical and small clinical studies show effects on EEG patterns consistent with deeper sleep. Community reports describe improved sleep quality, with some users describing jet-lag or sleep-reset use.

How is DSIP typically administered?

Clinical research used controlled routes including IV administration. The research-peptide market mostly discusses subcutaneous routes, but no FDA-approved dosing protocol and no modern pharmacokinetic framework exist for sleep use.

What are the side effects of DSIP?

Reported side effects are minimal. Occasional injection-site reactions, occasional vivid dreams or altered dream patterns. Long-term safety is not well-characterized; clinical research largely stalled in the 1990s-2000s.

Is DSIP FDA approved?

No. DSIP has never been FDA-approved. Despite decades of research interest, it has not progressed to registrational trials in the US or EU.

How much does DSIP cost?

No clinical retail price. On the research-chemical market it is inexpensive. Lower unit quantities compared to many peptides due to limited demand.

related peptides

• epithalon — other longevity-adjacent peptide with sleep claims
• selank — better-validated anxiolytic nootropic
• oxytocin — another neuropeptide with diffuse clinical claims

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.